MK-1064

DB15028InvestigationalSmall molecule

MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).

Mechanism: Pharmacologically active on Orexin receptor type 2
Curator reviewed
Formula / weight: C₂₄H₂₀ClN₅O₃ · 461.91 g/mol (avg)
Code names: MK-1064

Resolves to

Compound

UNIIO812716S9ECAS1207253-08-4ChEMBLCHEMBL3338866

Structure

InChIKeyCKTWQGHVNRYNCM-UHFFFAOYSA-NSMILESCOC1=CC=C(CNC(=O)C2=CC(=CN=C2C2=NC=CC=C2)C2=CN=CC(Cl)=C2)N=C1OC

Targets

O43614HCRTR2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-1064, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account